P
Paolo Petreni
Researcher at University of Florence
Publications - 13
Citations - 150
Paolo Petreni is an academic researcher from University of Florence. The author has contributed to research in topics: Lung cancer & Colorectal cancer. The author has an hindex of 5, co-authored 13 publications receiving 112 citations.
Papers
More filters
Journal ArticleDOI
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Roberta Minari,Paola Bordi,M. Del Re,Francesco Facchinetti,Francesca Mazzoni,Fausto Barbieri,Andrea Camerini,Camilla E. Comin,Letizia Gnetti,Cinzia Azzoni,Rita Nizzoli,Beatrice Bortesi,Eleonora Rofi,Paolo Petreni,Nicoletta Campanini,Giulio Rossi,Romano Danesi,Marcello Tiseo +17 more
TL;DR: Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790m/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.
Journal ArticleDOI
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Lorenzo Antonuzzo,Alice Lunghi,Paolo Petreni,Marco Brugia,Alice Laffi,Elisa Giommoni,Marinella Micol Mela,Francesca Mazzoni,Vanni Balestri,Francesco Di Costanzo +9 more
TL;DR: This paper provides a detailed description of clinical evidences upon the relationship between anti-angiogenic drugs and ONJ and concludes that ONJ must be always carefully investigated and prevented with a multidisciplinary approach involving oncologist, radiation oncologists and skilled dental practitioner when a cancer patient must begin a BP or an antiangIogenic treatment.
Journal ArticleDOI
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Erika Cecchin,Gabriele Perrone,Stefania Nobili,Jerry Polesel,E. De Mattia,Chiara Zanusso,Paolo Petreni,Sara Lonardi,Nicoletta Pella,Mario D'Andrea,Domenico Errante,Flavio Rizzolio,Teresita Mazzei,Ida Landini,Enrico Mini,Giuseppe Toffoli +15 more
TL;DR: MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.
Journal ArticleDOI
Effects of a home-based exercise rehabilitation program for cancer survivors.
Laura Stefani,Riggs J. Klika,Gabriele Mascherini,Francesca Mazzoni,Alice Lunghi,Cristian Petri,Paolo Petreni,Francesco Di Costanzo,Nicola Maffulli,Nicola Maffulli,Giorgio Galanti +10 more
TL;DR: Individually-prescribed home-based exercise programs were cost effective, safe and resulted in modest improvements in body composition, strength, and total body water distribution with little to no adverse effect on cardiac function.
Journal ArticleDOI
Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences:
Francesca Mazzoni,Paolo Petreni,M. Perna,Vieri Scotti,Stefano Bongiolatti,Lorenzo Livi,Francesco Di Costanzo,Luca Voltolini +7 more
TL;DR: 2 cases of EGFR-mutated locally advanced NSCLC treated in neoadjuvant setting with EGFR tyrosine kinase inhibitor at University of Florence/Careggi Hospital report significant reduction (downstaging) of the pulmonary mass and lymphadenopathies.